The added value of side specific systematic biopsy in patients diagnosed by magnetic resonance imaging-targeted prostate biopsy

We report a large multicentric study confirming the negligible added value of systematic biopsy when combined with magnetic resonance imaging (MRI)-targeted biopsy. The benefit in terms of the detection and upgrading of clinically significant prostate cancer was even less relevant when considering contralateral systematic biopsy relative to the MRI index lesion. We externally validate the Noujeim three-tier model that could be used in daily practice to improve the personalization of the diagnostic strategy while reducing the associated discomfort and overdiagnosis.